Skip to main content
ENDO 2026 Main banner

Daniel Frigo, PhD

Professor
University of Texas MD Anderson Cancer Center
Houston, TX, United States

Dr. Daniel Frigo, Ph.D. is currently Professor, Deputy Chair, and Scientific Director of Research in the Department of Cancer Systems Imaging (primary) and Professor in the Department of Genitourinary Medical Oncology (secondary) at The University of Texas MD Anderson Cancer Center. He received his B.S. in biochemistry from the University of Notre Dame and earned his Ph.D. in molecular and cellular biology from Tulane University. He was then awarded a postdoctoral fellowship and appointed to research scientist within the Department of Pharmacology & Cancer Biology at Duke University Medical Center in Durham, NC. He was appointed to a faculty position as an Assistant Professor at the University of Houston’s Center for Nuclear Receptors & Cell Signaling and the Department of Biology & Biochemistry in 2010. In 2017, he moved his laboratory to The University of Texas MD Anderson Cancer Center. He remains an Adjunct Professor with the University of Houston. Currently, the Frigo laboratory is focused on understanding how various signaling pathways — such as those regulated by the androgen receptor, CAMKK2, AMPK, and various tumor suppressors — drive the progression of prostate cancer subtypes. Interestingly, many of these signaling pathways converge at various metabolic nodes which causes a shift in oncogenic metabolism. These metabolic changes allow the cancer cells to utilize a diverse array of nutrients to the benefit of the cancer cell. A second major goal of the laboratory is to determine how systemic metabolism impacts tumor biology. Collectively, the long-term goal of our work is to exploit these newly uncovered pathways for therapeutic purposes.

Disclosure information not submitted.

Presentation(s):